Some clinical studies reported that serum adiponectin is negatively associated with bone mineral density (47–50), but other studies supported a positive correlation of serum adiponectin with bone mineral density in postmenopausal women with metabolic syndrome (51) and patients with type 2 diabetes mellitus (52). This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.